Orphazyme A/S (ORPH) News Today → Bitcoin Rockets To Record High But Buy THIS Instead (From Paradigm Press) (Ad) Free ORPH Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share HeadlinesStock Analysis All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineIt’s the first drug shown to slow Alzheimer’s. Why is is it off to a slow start?msn.com - April 13 at 11:29 AMLysine Is Important for the Body, and Is Generally a Safe Supplementmsn.com - April 12 at 12:36 PMZevra Therapeutics: Strong Buy on Strategic Financing and Promising Drug Portfoliomarkets.businessinsider.com - April 11 at 9:07 PMFrom fungi to feast: The rise of Mycoprotein as a sustainable protein solutionmsn.com - April 8 at 4:17 PMAsk A Doctor: What Diseases Cause Encephalopathy?msn.com - April 3 at 10:33 PMChemists discover a key protein in how lysosomes workmsn.com - April 1 at 2:52 PMOrry refuses to shake woman’s hand citing ‘germs,’ threatens legal action after her videomsn.com - March 28 at 8:40 PMA Guide To Pokémon's Poison Typemsn.com - March 28 at 8:40 PMUnderstanding what causes trastuzumab's cardiotoxicitymsn.com - March 18 at 10:53 PMHow a brash, red-haired orphan from P.E.I. continues to be a worldwide sensationmsn.com - March 16 at 5:47 PMSindica - A Novel, Patented Post-emergence Herbicide for Sugarcane from Atulmsn.com - March 14 at 3:51 PMSharing a Drink With Orphaned Opossum Babiesmsn.com - March 12 at 8:25 PMZevra adds bull at William Blair despite delay in arimoclomol decisionmsn.com - March 12 at 3:14 PM'Why haven't they shown us the original photo?' Anti-monarchist FUMES over Kate's apology - ‘Doesn't explain anything’msn.com - March 11 at 10:33 PMA.L.S. Drug Relyvrio Fails Clinical Trial and May Be Withdrawn From the Marketnytimes.com - March 10 at 10:22 AMAlnylam’s experimental drug for high blood pressure yields encouraging resultsmsn.com - March 5 at 1:59 PMFDA Extends Review of Zevra's Arimoclomol by Three Monthsmarketwatch.com - March 4 at 12:55 PMLadybug scents offer a more ecologically friendly way to protect cropsmsn.com - February 23 at 1:22 PMGen Alpha have a say on which names they consider to be 'old'msn.com - February 23 at 8:21 AMOne Piece: Is S-Hawk the Strongest Seraphim in the Series?yahoo.com - February 23 at 8:21 AMWhat Is The History Of Phenylketonuria? A Review By Doctorsmsn.com - February 22 at 4:10 PMNew Horizons in Chemical Biology: A Novel Approach to Synthesize Dibenzothiophene S-Oxidesmsn.com - January 31 at 3:48 PMChemical biology: A novel approach to synthesize dibenzothiophene s-oxidesmsn.com - January 31 at 3:48 PMLevi & Korsinsky, LLP Notifies Shareholders of Orphazyme (ORPH) an Upcoming Claims Deadline in a Class Action Settlementmarkets.businessinsider.com - December 5 at 2:52 PMWhat is Suboxone? Web sleuths speculate possible role of drug in Matthew Perry's hot tub death amid delayed toxicology reportmsn.com - November 4 at 12:13 PMMonkeypox ‘circulating for five years’ before 2022’s global health emergencymsn.com - November 3 at 12:32 PMMatthew Perry's autopsy has been completed but results are pending a toxicology reportmsn.com - October 29 at 11:26 PMOne Piece Reveals The Seraphim's Surprising Weaknessmsn.com - August 24 at 3:26 AMWhat’s Going Around: poison oakmsn.com - August 23 at 10:26 PMAlpha-gal syndrome: LI county a hot spot for tick-borne meat allergynypost.com - August 21 at 11:15 PMUS FDA approves higher dose of Regeneron's eye disease drug Eyleamsn.com - August 18 at 10:58 PMOrphazyme A/S (ORPHA)investing.com - August 17 at 8:46 AMRaven-Symoné suffered a seizure after having breast reductions, liposuction before turning 18yahoo.com - August 8 at 8:59 PMVistaGen's Fasedienol Trial For Social Anxiety Meets Primary Endpointmarketwatch.com - August 7 at 10:07 AMAstellas, Poseida Announce Investment To Support Poseida's Commitment To Cancer Cell Therapymarkets.businessinsider.com - August 7 at 10:07 AMUp to 450,000 in U.S. have red meat allergies due to alpha-gal syndrome spread by ticks, CDC sayscbsnews.com - July 28 at 12:59 AMHow to avoid contracting typhus, a bacterial infection spread through fleasmsn.com - July 23 at 7:40 AMPharmaMar's Odyssey: EMA On The Ropesforbes.com - July 19 at 7:11 PMaTyr Pharma: Admirable Strategy, Yet Efzofitimod's Success Remains Unlikelymsn.com - July 19 at 7:11 PMLosing AlphaTauri F1 Ride Is a Career 'Death Sentence' for Nyck de Vriesnews.yahoo.com - July 14 at 7:20 PMWhat To Know About Djokovic’s Nano Patch And Why Some Experts Call It ‘Pseudoscience’forbes.com - July 13 at 5:14 PMMaggie Siff and Erica Schmidt on a Williams Play ‘Shot Through With Desire’nytimes.com - July 12 at 9:11 PMOrganizers say village of Alpha’s 4th of July celebration was a successmsn.com - July 4 at 10:53 PMBioMarin’s Next Roctavian Challenge Is How To Successfully Commercialize Its Gene Therapy: Warranties May Be An Optionforbes.com - July 1 at 2:59 PMIt’s Not Just Endorphins—‘Hope Molecules’ Could Also Be Why You Feel So Good After Exercisingmsn.com - June 30 at 11:34 PMThe Story Of A Ukrainian Orphan Accused Of Lying About Her Age Is Too Messy For TVnews.yahoo.com - June 21 at 12:44 PMChange in managementfinance.yahoo.com - May 30 at 5:40 PMLadRx Announces Reverse Stock Splitmarketwatch.com - May 11 at 7:48 AMORPHAZYME A/S: Orphazyme Announces Publication of 2022 Financial Results and Annual Reportfinanznachrichten.de - April 26 at 8:42 AMOrphazyme Announces Publication of 2022 Financial Results and Annual Reportfinance.yahoo.com - April 25 at 8:23 PM Get Orphazyme A/S News Delivered to You Automatically Sign up to receive the latest news and ratings for ORPH and its competitors with MarketBeat's FREE daily newsletter. Email Address Could Bitcoin Literally FORCE This Crypto To Rocket Up? (Ad)Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring… >>Click here to find out what it is. ORPH Media Mentions By Week ORPH Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ORPH News Sentiment▼-0.020.45▲Average Medical News Sentiment ORPH News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ORPH Articles This Week▼31▲ORPH Articles Average Week Get Orphazyme A/S News Delivered to You Automatically Sign up to receive the latest news and ratings for ORPH and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Lipocine News Today Aptorum Group News Today Acurx Pharmaceuticals News Today Spruce Biosciences News Today Acasti Pharma News Today Eyenovia News Today Aileron Therapeutics News Today Aprea Therapeutics News Today Lexaria Bioscience News Today DURECT News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ORPH) was last updated on 4/18/2024 by MarketBeat.com Staff From Our PartnersRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldIRS Loophole Gives Americans An Escape From InflationBirch GoldHe Is Giving Away BitcoinCrypto Swap Profits[Urgent!] Generational Wealth GameplanCrypto 101 MediaThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThe “Perfect Storm” for GoldGold Safe ExchangeThe "Smart Money" Is Ready for May 1st Are You?Stansberry ResearchRich Dad Poor Dad Author Shocks Millions With 2024 Crash WarningAmerican Hartford Gold Group Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Orphazyme A/S Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.